What this study is
The study is a Phase II clinical trial. Patients will receive intensity modulated total body irradiation (TBI) at a dose of 3 Gy with standard fludarabine/ i.v. cyclophosphamide conditioning prior to human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell transplant (HSCT).
The primary objective of the study is to determine the engraftment at Day +60 following HLA-haploidentical hematopoietic stem cell transplant protocol using immunosuppressive agents and low-dose total body irradiation (TBI) for conditioning and post-transplant cyclophosphamide in patients with sickle cell disease.
What's being tested
- ATG
Intervention · DRUG
0.5 mg/kg IV on day -9, and 2 mg/kg on days -8 and day -7
- fludarabine
Intervention · DRUG
30 mg/m2 IVPB daily for day -6 (6 days before stem cell infusion) through day -2
- cyclophosphamide
Intervention · DRUG
14.5 mg/kg IV on days -6 and -5 and 50 mg/kg/d on days +3 and +4
- Total body irradiation
Intervention · RADIATION
3 Gy on day -1
- Stem cell infusion
Intervention · PROCEDURE
Stem cell product infused according to BMT unit policy on day 0.
- Sirolimus
Intervention · DRUG
loading dose of 15 mg followed by 5 mg per day on day +5
- mycophenolate mofetil
Intervention · DRUG
1 g every 8 h (until day 35) will be started on day 5
Study details
- Official title
- A Phase II Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
- Sponsor
- University of Illinois at Chicago
- Conditions
- Sickle Cell Disease
- Enrolling
- 50 people
- Starts
- 2017-03-20
- Est. completion
- 2026-05
- Design
- Open-label, single group, Phase 2
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 16 Years – 60 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- Patient Eligibility:
- Patients with sickle cell disease are eligible if they have any of the following complications: 1.1 Stroke or central nervous system event lasting longer than 24 hours 1.2 Frequent vaso-occlusive pain episodes, defined as ≥ 3 per year requiring emergency room, acute care center, hospital admissions, or home bedrest leading to absence from work or school. 1.3 Recurrent episodes of priapism, defined as ≥ 2 per year requiring emergency room visits 1.4 Acute chest syndrome with recurrent hospitalizations, defined as ≥ 2 lifetime events 1.5 Red-cell alloimmunization (≥ 2 antibodies) during long-term transfusion therapy 1.6 Bilateral proliferative retinopathy with major visual impairment in at least one eye 1.7 Osteonecrosis of 2 or more joints 1.8 Sickle cell nephropathy, defined by a GFR < 90mL/min/1.73m2 or the presence of macroalbuminuria (urine albumin > 300 mg/g creatinine) 1.9 Pulmonary hypertension, defined by a mean pulmonary arterypressure >25mmHg
- Age 16-60 years
- Karnofsky performance status of 60 or higher (Appendix A)
- Adequate cardiac function, defined as left ventricular ejection fraction ≥ 40%
- Adequate pulmonary function, defined as diffusion lung capacity of carbon monoxide ≥ 50% predicted (after adjustment for hemoglobin concentration)
- Estimated GFR ≥ 50mL/min/1.73m2 as calculated by the modified MDRD equation
- ALT ≤ 3x upper limit of normal
- HIV-negative
- Patient is not pregnant
- Patient is able and willing to sign informed consent
- Patient does not have a fully HLA-matched sibling donor
- Patient has an HLA-haploidentical relative Donor Eligibility Relatives (parents, offspring, siblings, aunts/uncles, cousins) will be tested by molecular typing of HLA class I (A, B, and C) and class II (DRB1) at low resolution. Only those that are an HLA-haploidentical match (≥ 4/8) will be considered as a potential donor. NOTE: If during testing, a fully HLA-matched sibling donor is found and is willing to donate his/her stem cells, the potential subject will not be eligible for this protocol. Donor consent will be obtained as per standard protocol of the bone marrow transplant unit.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openUniversity of Illinois at Chicago
Chicago, Illinois, United States
- Damiano Rondelli, MD · Contact312-413-3547drond@uic.edu
Recruiting
Study team
Sponsor
University of Illinois at Chicago
Study ID 2016-1152
Principal investigator
Damiano Rondelli, MD
University of Illinois at Chicago
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.